In total, from January to November 2025, finished pharmaceutical products manufactured in Russia amounted to RUB 902.0 billion (at manufacturers’ ex-factory prices, including VAT). In rouble terms, growth versus the same period of 2024 reached 16.7%. According to the "Pharmaceutical Production in Russia" database of the analytical company RNC Pharma, during the first eleven months of 2025 pharmaceutical companies localised in Russia placed more than 3.61 billion packs of finished medicines on the market, corresponding to 76.6 billion minimum dosing units (MDUs). Over the year, total pharmaceutical output in Russia declined by 3.7% in packs, while demonstrating growth of 1.3% in minimum dosing units, driven by the trend towards larger consumer pack sizes. In January–November 2025, each pack of medicines produced domestically contained an average of 21.2 MDUs, compared with just over 20.1 units a year earlier.

In November 2025, manufacturers’ activity was slightly below October levels; nevertheless, companies localised in Russia shipped 352.1 million packs of finished medicines to the market. This was 0.3% less than a year earlier, while MDUs showed positive dynamics, with shipments up 6.3% to a total of 7.7 billion units. In value terms, total shipments in November 2025 reached RUB 92.3 billion, 13.3% higher year on year.

In 2025, adjustments in overall production volumes were driven exclusively by a decline in over-the-counter (OTC) medicines. In January–November 2025, shipments of OTC products fell by 9.5% in packs, whereas production of prescription (Rx) medicines increased by 2.2% compared with January–November 2024. Notably, the trend towards larger consumer packs is observed in both segments, but is more pronounced for prescription medicines.

The absolute leader in terms of physical production volume in January–November 2025 was Ozon Pharmaceuticals, which produced 33.6 million packs, accounting for approximately 9.2% of total national output. Previously, Pharmstandard had held the leading position; the change in leadership occurred only in the current year. It is noteworthy that Ozon Pharmaceuticals demonstrates one of the highest growth rates among leading manufacturers: compared with January–November 2024, its shipments increased by 25% in packs. The absolute leader in growth rates among the top ten manufacturers over the analysed period was Wellfarm Group (+32% in packs). Both companies specialise in a broad portfolio of generics.

Among major producers of branded medicines, AstraZeneca demonstrated strong shipment dynamics (+43%). In 2025, the company significantly increased production of Forxiga at its own manufacturing site in the Kaluga Region, while shipments of the Betaloc and Nexium brands also rose substantially. Menarini (+27%) should also be highlighted, with growth primarily driven by increased production of Mig, which is manufactured at the Novartis Neva facility in St. Petersburg.

Figure. Volume of finished pharmaceutical production in Russia (including medicines manufactured by foreign pharmaceutical companies at their own and contract facilities) from January 2024 to November 2025, in physical terms (packs) and value terms (RUB, manufacturers’ prices, including VAT).